HealthCap
Edit

HealthCap

https://www.healthcap.eu
Last activity: 18.03.2025
Active
Invests in categories: MedTechDevelopmentBioTechMarketProductDrugCareITAdTechData
HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.

Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales.

Over the years, HealthCap companies have developed 30 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.
News
2.11K
Portfolio
13
Persons
2
Mentions
23
Location: Sweden, Stockholm
Employees: 11-50
Founded date: 1996
Investment Type: Venture Capital
Investment Stage: Series A

Portfolio 13

DateNameWebsiteTotal RaisedLocation
16.11.2022Prothelia ...prothelia.com--
26.06.2022Priotherapriothera.com$55.3M-
13.06.2022Ariceum Th...ariceum-therapeutics.com$79.19MGermany, B...
22.07.2021Hemab Ther...hemab.com$190MDenmark, C...
19.02.2021Tisbury Ph...tisburypharmaceuticals.com$32MUnited Sta...
19.02.2021RSPR Pharm...rsprpharma.com-Sweden, Up...
19.02.2021Trimb Heal...trimb.se--
19.02.2021ReVENT Med...reventmedical.com-United Sta...
19.02.2021SpineVisio...spinevision.com--
19.11.2020SynOx Ther...synoxtherapeutics.com$323.8MIreland, D...
Show more

Persons 2

DateFirst NameLast NameTitleLinkedInLocation
-Carl-JohanDalsgaardVenture Pa...linkedin.c...-
-DagRichterxlinkedin.c...-

News 2110

DateTitleDescription
25.05.2023Strong long-term results with CERAMENT®G for severe open fractures – study from Manchester University HospitalPublished: 2023-05-25 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep i...
23.05.2023Spruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES GalaJavier Szwarcberg, M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–May 22, 2023– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focuse...
23.05.2023Vicore obtains significant new patent protection for C21 in the USStockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase...
19.05.2023Vicore reports new 36-week data from the AIR trial demonstrating sustained disease stabilization and increase in lung function in IPF patientsStockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, today announces an updated interim analysis of its AIR phase 2a trial wi...
17.05.2023Vicore to host webcast with updated AIR trial results after presentation at the ATS congressStockholm, May 17, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, will hold a webcast including a Q&A session to present interim r...
16.05.2023Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business OperationsDOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targe...
15.05.2023Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesCAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Top...
12.05.2023Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results And Clinical Program UpdatesFPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Clinical p...
12.05.2023UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and CancerBerlin, Germany, and Brussels, Belgium, 11 May 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers,and UCB (EURONEXT BRUSS...
12.05.2023Oncopeptides presents new data at the European Haematology Association meetingMay 11, 2023 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and saf...
Show more

Mentions in press and media 23

DateTitleDescription
18.03.2025Navigating Change: The Evolving Landscape of Biotechnology and GovernanceIn the fast-paced world of biotechnology, change is the only constant. Companies like Intervacc and Circio Holding ASA are at the forefront, navigating through financial commitments and governance adjustments. Their journeys reflect the bro...
18.03.2025Oncorena receives FDA approval to initiate studies in the USOncorena receives FDA approval to initiate studies in the US Tue, Mar 18, 2025 08:15 CET Report this content Lund, Sweden, March 18, 2025 - Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate ...
17.03.2025Intervacc announces changes in the Nomination CommitteeIntervacc announces changes in the Nomination Committee Mon, Mar 17, 2025 17:40 CET Report this content Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the rece...
05.03.2025Digital mental health startup HelloBetter secures €6M and eyes French market entryMental health startup HelloBetter has secured over €6 million in cash and media-for-equity, bringing its funding to €31 million. HelloBetter is a pioneer in digital mental health research. Founded in 2015 by Prof Dr David Ebert, Dr Hanne Ho...
13.02.2025Year-end report January – December 2024Year-end report January – December 2024 Thu, Feb 13, 2025 08:30 CET Report this content The Group in summary 01/10/24 01/10/23 Full year Full year -31/12/24 -31/12/23 2024 2023 Net sales 4 127 1 626 11 787 8 015 Operating result -18 505 -20...
20.09.2022Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial TherapiesWhat You Should Know: Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondri...
25.05.2022Annual General Meeting in Oncopeptides AB (publ)Annual General Meeting in Oncopeptides AB (publ) Wed, May 25, 2022 15:15 CET Report this content STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stoc...
10.03.2022Saying hello to better mental health! German startup unlocks €10 million for digital therapeuticsBerlin-based digital mental healthcare company HelloBetter has raised €4 million extension of its recently announced €6 million Series A funding. This brings the total investment raised in the round to €10 million. The round was led by Mass...
21.06.2021Sweden’s medical history digitiser and collaboration platform Doctrin raises €13 millionDoctrin, a medtech startup hailing from Stockholm, has raised €13 million to further its efforts of providing, “patient-centric healthcare, free from barriers”. In doing so, Doctrin is now looking beyond its existing markets of Sweden, the ...
29.04.2021Ysios Capital lidera una inversión de €51 millones en Adcendo. Acuden también Novo Seeds, RA Capital Management, HealthCap y Gilde29/04/2021 Nota de prensa YSIOS CAPITAL LIDERA UNA INVERSIÓN DE €51 MILLONES EN ADCENDO. − Adcendo (Copenhague, Dinamarca), es una compañía biotecnológica especializada en el desarrollo de fármacos inmunoconjugados para el tratamiento de...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In